株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ヒトパラインフルエンザウイルス3型感染症:パイプライン製品の分析

Human Parainfluenza Virus 3 Infections - Pipeline Review, H2 2018

発行 Global Markets Direct 商品コード 619904
出版日 ページ情報 英文 33 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.52円で換算しております。
Back to Top
ヒトパラインフルエンザウイルス3型感染症:パイプライン製品の分析 Human Parainfluenza Virus 3 Infections - Pipeline Review, H2 2018
出版日: 2018年09月28日 ページ情報: 英文 33 Pages
概要

ヒトパラインフルエンザウイルス3型感染症は、乳幼児に呼吸器疾患を引き起こさ、生命をも脅かすような感染症です。主な症状には、発熱やせき、鼻水、偽膜性喉頭炎 (クループ)、細気管支炎、喘鳴、咽頭痛などが含まれています。主な治療薬には、痛み止め・解熱用の市販薬 (OTC) などがあります。

当レポートでは、世界各国でのヒトパラインフルエンザウイルス3型感染症の治療薬のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向 (治験が中断中/中止済みの製品ほか) などを調査しております。

目次

  • イントロダクション
    • 分析範囲
  • 口腔乾燥症の概要
  • ヒトパラインフルエンザウイルス3型感染症:治療薬の開発
    • パイプラインの概要
    • 企業別のパイプライン動向
    • 大学・研究機関別のパイプライン動向
    • 企業で開発中の製品
    • 大学・研究機関で開発中の製品
  • ヒトパラインフルエンザウイルス3型感染症:治療薬の評価
    • 標的別
    • 作用機序別
    • 投与経路別
    • 分子の種類別
  • ヒトパラインフルエンザウイルス3型感染症:治療薬の開発に従事している企業
    • 3-V Biosciences Inc
    • Amarillo Biosciences Inc
    • Moderna Therapeutics Inc
  • ヒトパラインフルエンザウイルス3型感染症:薬剤のプロファイル
    • インターフェロンα
      • 製品概略
      • 作用機序
      • 研究開発 (R&D) の進捗状況
    • mRNA-1653
    • Paradase
    • ヒトパラインフルエンザウイルス1型・3型感染症向けの、ヘマグルチニン・ノイラミニダーゼ阻害用小分子
    • TVB-3567
  • ヒトパラインフルエンザウイルス3型感染症:休止状態のプロジェクト
  • ヒトパラインフルエンザウイルス3型感染症:開発が中止された製品
  • 付録
図表

List of Tables

  • Number of Products under Development for Human Parainfluenza Virus 3 Infections, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Human Parainfluenza Virus 3 Infections - Pipeline by 3-V Biosciences Inc, H2 2018
  • Human Parainfluenza Virus 3 Infections - Pipeline by Amarillo Biosciences Inc, H2 2018
  • Human Parainfluenza Virus 3 Infections - Pipeline by Moderna Therapeutics Inc, H2 2018
  • Human Parainfluenza Virus 3 Infections - Dormant Projects, H2 2018
  • Human Parainfluenza Virus 3 Infections - Discontinued Products, H2 2018

List of Figures

  • Number of Products under Development for Human Parainfluenza Virus 3 Infections, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products by Targets, H2 2018
  • Number of Products by Stage and Targets, H2 2018
  • Number of Products by Mechanism of Actions, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018
目次
Product Code: GMDHC10842IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Parainfluenza Virus 3 Infections - Pipeline Review, H2 2018, provides an overview of the Human Parainfluenza Virus 3 Infections (Infectious Disease) pipeline landscape.

Human parainfluenza virus 3 is a life-threatening infection that causes respiratory illnesses in infants and young children. Symptoms include fever, cough, runny nose, croup, bronchiolitis, wheezing and sore throat. Treatment includes over-the-counter medications for pain and fever.  

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Human Parainfluenza Virus 3 Infections - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Human Parainfluenza Virus 3 Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Parainfluenza Virus 3 Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Human Parainfluenza Virus 3 Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Human Parainfluenza Virus 3 Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Human Parainfluenza Virus 3 Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Human Parainfluenza Virus 3 Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Human Parainfluenza Virus 3 Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Human Parainfluenza Virus 3 Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Human Parainfluenza Virus 3 Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Human Parainfluenza Virus 3 Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Human Parainfluenza Virus 3 Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Human Parainfluenza Virus 3 Infections - Overview
    • Human Parainfluenza Virus 3 Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Human Parainfluenza Virus 3 Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Human Parainfluenza Virus 3 Infections - Companies Involved in Therapeutics Development
    • 3-V Biosciences Inc
    • Amarillo Biosciences Inc
    • Moderna Therapeutics Inc
  • Human Parainfluenza Virus 3 Infections - Drug Profiles
    • interferon alpha - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mRNA-1653 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Paradase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Hemagglutinin and Neuraminidase for Human Parainfluenza Virus 1 and 3 Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TVB-3567 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Human Parainfluenza Virus 3 Infections - Dormant Projects
  • Human Parainfluenza Virus 3 Infections - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top